DE60115840T2 - Formulierung mit mehrfach gepulster wirkstofffreisetzung - Google Patents
Formulierung mit mehrfach gepulster wirkstofffreisetzung Download PDFInfo
- Publication number
- DE60115840T2 DE60115840T2 DE60115840T DE60115840T DE60115840T2 DE 60115840 T2 DE60115840 T2 DE 60115840T2 DE 60115840 T DE60115840 T DE 60115840T DE 60115840 T DE60115840 T DE 60115840T DE 60115840 T2 DE60115840 T2 DE 60115840T2
- Authority
- DE
- Germany
- Prior art keywords
- drug
- dose
- composition
- release
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 238000009472 formulation Methods 0.000 title abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 50
- 229940079593 drug Drugs 0.000 claims abstract description 45
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229960001344 methylphenidate Drugs 0.000 claims abstract description 40
- 239000008188 pellet Substances 0.000 claims abstract description 11
- 239000002702 enteric coating Substances 0.000 claims abstract description 10
- 238000009505 enteric coating Methods 0.000 claims abstract description 10
- 239000000725 suspension Substances 0.000 claims abstract description 10
- 235000015110 jellies Nutrition 0.000 claims abstract description 6
- 239000008274 jelly Substances 0.000 claims abstract description 6
- 238000004090 dissolution Methods 0.000 claims abstract description 4
- 239000007787 solid Substances 0.000 claims description 16
- 239000000499 gel Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 239000004005 microsphere Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 2
- 235000007983 food acid Nutrition 0.000 claims description 2
- 208000013403 hyperactivity Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000873 masking effect Effects 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 238000012377 drug delivery Methods 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 239000006072 paste Substances 0.000 abstract description 16
- 239000011859 microparticle Substances 0.000 abstract description 6
- 229940034610 toothpaste Drugs 0.000 abstract description 3
- 239000000606 toothpaste Substances 0.000 abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000000576 coating method Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 3
- 239000013583 drug formulation Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 3
- 235000021400 peanut butter Nutrition 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 240000007651 Rubus glaucus Species 0.000 description 2
- 235000011034 Rubus glaucus Nutrition 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940099204 ritalin Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960001033 methylphenidate hydrochloride Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Confectionery (AREA)
- General Preparation And Processing Of Foods (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17685300P | 2000-01-19 | 2000-01-19 | |
| US176853P | 2000-01-19 | ||
| PCT/US2001/001925 WO2001052813A1 (en) | 2000-01-19 | 2001-01-19 | Multi-spike release formulation for drug delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60115840D1 DE60115840D1 (de) | 2006-01-19 |
| DE60115840T2 true DE60115840T2 (de) | 2006-07-13 |
Family
ID=22646129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60115840T Expired - Fee Related DE60115840T2 (de) | 2000-01-19 | 2001-01-19 | Formulierung mit mehrfach gepulster wirkstofffreisetzung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6555127B2 (enExample) |
| EP (1) | EP1248594B1 (enExample) |
| JP (1) | JP2003520223A (enExample) |
| AT (1) | ATE312595T1 (enExample) |
| AU (1) | AU2001231018A1 (enExample) |
| DE (1) | DE60115840T2 (enExample) |
| DK (1) | DK1248594T3 (enExample) |
| ES (1) | ES2258072T3 (enExample) |
| WO (1) | WO2001052813A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| US20020187192A1 (en) * | 2001-04-30 | 2002-12-12 | Yatindra Joshi | Pharmaceutical composition which reduces or eliminates drug abuse potential |
| US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
| WO2003004030A1 (en) * | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Oxymorphone controlled release formulations |
| WO2003004033A1 (en) * | 2001-07-06 | 2003-01-16 | Penwest Pharmaceuticals Company | Sustained release formulations of oxymorphone |
| EP1429730A4 (en) * | 2001-09-26 | 2010-06-16 | Penwest Pharmaceuticals Compan | OPIOID FORMULATIONS WITH REDUCED ABUSE POTENTIAL |
| AU2003220125B2 (en) | 2002-03-20 | 2006-06-15 | Mannkind Corporation | Inhalation apparatus |
| CA2395819A1 (en) * | 2002-08-13 | 2004-02-13 | Bernard Charles Sherman | Dual-spike release formulation for oral drug delivery |
| US7988993B2 (en) * | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
| EP2112920B1 (en) * | 2003-06-26 | 2018-07-25 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| CA2561855A1 (en) | 2004-04-12 | 2005-10-20 | Pfizer Products Inc. | Taste-masked drugs in rupturing multiparticulates |
| US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US20060024361A1 (en) * | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
| PL1786784T3 (pl) | 2004-08-20 | 2011-04-29 | Mannkind Corp | Kataliza syntezy diketopiperazyn |
| EP2314298B1 (en) | 2004-08-23 | 2015-05-27 | MannKind Corporation | Microparticles comprising diketopiperazine salts for drug delivery |
| US10624858B2 (en) * | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| AU2006290870B2 (en) | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| DK1986679T3 (da) | 2006-02-22 | 2017-11-20 | Mannkind Corp | Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof |
| US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
| EP2018160B1 (en) | 2006-03-16 | 2011-12-14 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
| WO2007112581A1 (en) | 2006-04-03 | 2007-10-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
| EP2010162A4 (en) * | 2006-04-03 | 2013-01-09 | Isa Odidi | COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT |
| US10960077B2 (en) * | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| EP2091519B1 (en) | 2006-11-30 | 2015-06-24 | Bend Research, Inc | Multiparticulates of spray-coated drug and polymer on a meltable core |
| US11116728B2 (en) | 2006-11-30 | 2021-09-14 | Bend Research, Inc. | Multiparticulates of spray-coated drug and polymer on a meltable core |
| US8202542B1 (en) | 2007-05-31 | 2012-06-19 | Tris Pharma | Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings |
| US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| CN103252007B (zh) | 2008-06-13 | 2016-06-22 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
| JP5479465B2 (ja) | 2008-06-20 | 2014-04-23 | マンカインド コーポレイション | 吸入努力をリアルタイムにプロファイルする対話式機器および方法 |
| TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| CN102238946B (zh) * | 2008-11-07 | 2014-11-26 | 株式会社三养生物制药 | 用于哌醋甲酯的控制释放的药物组合物 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| EP2676695A3 (en) | 2009-03-11 | 2017-03-01 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| KR101875969B1 (ko) | 2009-06-12 | 2018-07-06 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
| US8709477B2 (en) * | 2009-08-13 | 2014-04-29 | Kremers Urban Pharmaceuticals, Inc` | Pharmaceutical dosage form |
| WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
| CN105667994B (zh) | 2011-04-01 | 2018-04-06 | 曼金德公司 | 用于药物药盒的泡罩包装 |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| WO2013063160A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
| SG11201500218VA (en) | 2012-07-12 | 2015-03-30 | Mannkind Corp | Dry powder drug delivery systems and methods |
| ES2717469T3 (es) | 2012-08-15 | 2019-06-21 | Tris Pharma Inc | Comprimido masticable de metilfenidato de liberación prolongada |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| EP2970149B1 (en) | 2013-03-15 | 2019-08-21 | MannKind Corporation | Microcrystalline diketopiperazine compositions and methods |
| CN105451716A (zh) | 2013-07-18 | 2016-03-30 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
| WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002776A (en) * | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
| US4904476A (en) * | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US5288479A (en) | 1989-01-17 | 1994-02-22 | Sterling Drug, Inc. | Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof |
| US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5885616A (en) * | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
| US20010055613A1 (en) * | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
| HU230454B1 (hu) * | 1998-11-02 | 2016-07-28 | Alkermes Pharma Ireland Limited | Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény |
| US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| US6217904B1 (en) * | 1999-04-06 | 2001-04-17 | Pharmaquest Ltd. | Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant |
-
2001
- 2001-01-19 US US09/766,394 patent/US6555127B2/en not_active Expired - Fee Related
- 2001-01-19 EP EP01903167A patent/EP1248594B1/en not_active Expired - Lifetime
- 2001-01-19 AU AU2001231018A patent/AU2001231018A1/en not_active Abandoned
- 2001-01-19 DE DE60115840T patent/DE60115840T2/de not_active Expired - Fee Related
- 2001-01-19 AT AT01903167T patent/ATE312595T1/de not_active IP Right Cessation
- 2001-01-19 DK DK01903167T patent/DK1248594T3/da active
- 2001-01-19 JP JP2001552861A patent/JP2003520223A/ja not_active Withdrawn
- 2001-01-19 ES ES01903167T patent/ES2258072T3/es not_active Expired - Lifetime
- 2001-01-19 WO PCT/US2001/001925 patent/WO2001052813A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001052813A1 (en) | 2001-07-26 |
| AU2001231018A1 (en) | 2001-07-31 |
| EP1248594A1 (en) | 2002-10-16 |
| ES2258072T3 (es) | 2006-08-16 |
| ATE312595T1 (de) | 2005-12-15 |
| DE60115840D1 (de) | 2006-01-19 |
| US6555127B2 (en) | 2003-04-29 |
| EP1248594B1 (en) | 2005-12-14 |
| DK1248594T3 (da) | 2006-02-06 |
| US20010046472A1 (en) | 2001-11-29 |
| JP2003520223A (ja) | 2003-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60115840T2 (de) | Formulierung mit mehrfach gepulster wirkstofffreisetzung | |
| DE69635993T2 (de) | Gelierte arzneimittel zur oralen verabreichung | |
| DE69217191T2 (de) | Multipartikel-tablette mit schnellauflösbarkeit | |
| DE60319355T2 (de) | Kaubare weichkapsel | |
| RU2093143C1 (ru) | Лекарственная форма и способ ее получения | |
| DE3538429C2 (de) | Pulver mit gesteuerter Freisetzung, Verfahren zu dessen Herstellung und dessen Verwendung | |
| DE68915132T2 (de) | Verfahren zur Behandlung von Periodontitis durch protrahierte Wirkstoffabgabe von Arzneimitteln in der Zahnhöhle, Zusammensetzung davon und Vorrichtung zur Verabreichung. | |
| DE69016755T2 (de) | Pharmazeutische Zubereitung mit verzögerter Freisetzung zur Behandlung periodontaler Erkrankungen. | |
| DE69727000T2 (de) | Arzneimittel mit verzögerter Wirkstoffabgabe enthaltend Venlafaxin | |
| DE1617374C2 (de) | Verfahren zum Herstellen eines pharmazeutischen Präparates mit verzögerter analgetischer Wirkung | |
| DE69915184T2 (de) | Pharmazeutische Formulierung und Dosierform bestehend aus Polysacchariden zur kontrollierten Wirkstoff-Freisetzung im Dickdarm | |
| DE2414868C3 (de) | Teilchenförmige Arzneimittel | |
| DE69011766T2 (de) | Wässerige Arzneisuspension für im wesentlichen wasserunlösliche Arzneiwirkstoffe. | |
| DE3787829T2 (de) | System für die Periodontaltasche zur kontrollierten Drogenfreisetzung. | |
| DE69309701T3 (de) | Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung periodontaler erkrankungen | |
| DE69227467T2 (de) | Intrabukkal desintegrierende zubereitung und ihre herstellung | |
| DE3779933T2 (de) | Xanthangummienthaltende arzneimittelformulierung mit verzoegerter freisetzung. | |
| DE69710756T2 (de) | Orale zeitversetzt schnell freisetzende formulierung sowie verfahren zu deren herstellung | |
| DE69009175T2 (de) | Verwendung eines alkoholfreien Verabreichungssystems für Wirkstoffe, welche oral eingenommen werden. | |
| DE60126089T2 (de) | Verabreichungssystem | |
| DE69419260T2 (de) | Orale dosierungsform für tiere, verfahren zu ihrer herstellung und verwendungen | |
| DE69530759T2 (de) | Filmbeschichtete tablette, die paracetamol und domperidone enthält | |
| DE60008497T2 (de) | Arzneimittel zur oralen verabreichung | |
| DE69919003T2 (de) | Acetaminophen-formulierung mit verlängerter freisetzung | |
| DE69922664T2 (de) | Acetaminophen mit verlängerter freisetzung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: MANNKIND CORP., VALENCIA, CALIF., US |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |